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Acetic acid (AcA) 
Acetonitrile (ACN) 
Actin (A) (UNIPROT ID:P62736) 
Cardiac Muscle Tissue (CMT) 
Dithiothreitol (DTT)  
Ethanol (EtOH) 
Fatty Acid Binding Protein 4 (FBP4) (UNIPROT ID: P15090) 
Formalin-Fixed Paraffin-Embedded (FFPE) 
Formic acid (FOA) 
Horse Apomyoglobin (HA) (UNIPROT ID: P68082) 
Immunoglobulins G (IgGs) 
IgG Heavy Chains, Type 1-4 (HCs) (UNIPROT ID: P01857) 
Immunoglobulin Light Chain, κ−Type (κ−LC) (UNIPROT ID: P01834) 
Immunoglobulin Light Chain, λ−Type (λ−LC) (UNIPROT ID: P0CG04) 
Ion extraction chromatogram (XIC) 
Laser Micro-Dissection (LMD) 
Methanol (MeOH) 
Multiple Reaction Monitoring (MRM) 
Positive Electrospray (ESI+) 
Sodium dodecyl sulfate (SDS) 
Subcutaneous adipose tissue (SAT) 
Transthyretin (TTR) (UNIPROT ID: P02766) 
Tris(hydroxymethyl)-aminomethane hydrochloride (Tris-HCl) 
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Background: Amyloidosis is a life threatening disease caused by deposition of various types of 
blood serum proteins in organs and tissues. Knowing the type of protein involved is the basis of a 
correct diagnosis and personalized medical treatment. While the classical approach uses 
immunohistochemistry, in recent years, laser micro-dissection, followed by high resolution LC-
MS/MS, has been shown to provide superior diagnostic sensitivity and specificity. This techniques, 
however, is only available at major reference proteomics centers. 
Objective: To perform clinical amyloid protein typing using low-resolution mass spectrometry and 
no laser micro dissection (LMD), we developed a targeted proteomics approach for the 
determination of both frequently encountered amyloid proteins (i.e., κ and -λ immunoglobulin light 
chains and transthyretin (TTR)) and specific reference proteins (i.e., actin (A) for cardiac muscle 
tissue, or fatty acid binding protein 4 (FBP4) for subcutaneous adipose tissue) in histologic specimens. 
Method: Small tissue fragments and/or histological sections were digested to yield a protein 
mixture that was subsequently reduced, alkylated and trypsinized to obtain a peptide mixture. After 
SPE purification and LC separation, proteotypic peptides were detected by their MRM transitions. 
Results: The method showed high specificity and sensitivity for amyloid protein proteotypic 
peptides. LODs were 1.0, 0.1, 0.2 picomoles in cardiac muscle tissue (CMT) and 0.1, 0.2, 0.5 
picomoles in subcutaneous adipose tissue (SAT) for TTR, κ-, and λ-LC proteins, respectively. 
Amyloid to tissue-specific protein signal ratios correlated with the presence of amyloid deposits in 
clinical samples. 
Conclusions: This targeted proteomics approach enables sensitive and specific discrimination of 
amyloidosis affected tissues for the purpose of clinical research. 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
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Amyloidosis is a life threatening pathology caused by extracellular deposition of insoluble fibrillar 
aggregates of a variety of blood serum proteins and/or their low molecular subunits (5 to 25 kD) [1–
7] in organs and tissues. A variety of organs, such as the heart, kidney, liver, and autonomic nervous 
system can be affected by amyloidosis [8,9]. Although the pathogenesis is unknown, at least 30 
proteins types have been determined to be involved in the formation of amyloid fibrils in humans 
[10]. 
Diagnosis of amyloidosis is primarily based on histological examination. Amyloid fibrils have a 
characteristic appearance and generate green birefringence under polarized light when stained with 
Congo red dye. Electron microscopy can also be used to reveal the presence of rigid, non-branching 
fibrils, 7.5-10 nm in diameter, disrupting surrounding tissues [13-15]. Proper classification of 
amyloidosis also requires an understanding of fibril distribution (i.e., systemic or localized) and 
protein composition. Accurate interpretation of the protein composition of amyloid fibrils, also 
known as amyloid typing, is critical for personalizing medical treatment since prognosis and 
treatment can vary substantially for each sub-type, ranging from targeted drug therapy to intensive 
chemotherapy, or even multi-organ transplant [10-12]. 
Historically, amyloid typing using immunohistochemistry and immunofluorescence methods has 
been widely employed. However, these methods are hindered by limited antibody availability, non-
specific signal interference due to tissue contamination from serum proteins, and false-negative 
signals due to the loss of epitopes in fixed and stained tissue sections. The disadvantages of 
antibody-based approaches have been comprehensively reviewed in the literature [13–15]. 
More recently, literature reports have outlined an approach to amyloidosis protein typing that 
employs laser micro dissection (LMD) to select fibrils from histological sections, and High 
Resolution (HR) Liquid Chromatography coupled to Tandem Mass Spectrometry (LC-MS/MS) to 
identify peptides obtained after a top-down proteomic processing of isolated fibrils [16-18]. While 
this approach has revolutionized the field of tissue protein typing for amyloidosis, it requires highly 
specialized instrumentation and a multidisciplinary team of trained professionals; its application is, 
therefore, limited to only a few reference proteomics centers throughout the world. 
Here, we present the development of a standard-resolution LC-MS/MS targeted proteomics 
approach [19,20] with the potential to enable MS/MS-based identification of amyloid proteins. We 
focus on cases of systemic amyloidosis with myocardial involvement that we frequently encounter 
in our clinical practice. 
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The samples most frequently examined in this work were cardiac muscle tissue (CMT) biopsies, 
and/or their sections fixed on optical glass slides for immunohistological examination, since these 
were already part of our routine procedures for diagnosis of amyloidosis. In addition, a modified 
procedure for processing subcutaneous adipose tissue (SAT) was developed, since this sample type 
involves a less invasive bioptic procedure that has been demonstrated to be convenient and 
informative in diagnosis of systemic amylodosis [21,22]. 
The three most frequent and clinically challenging subtypes of amyloidosis with cardiac 
involvement, as reported in the literature, are: (i) the κ− or λ type immunoglobulin light 
chains (LCs)-related amyloidosis (AL) caused by fibrillar deposits of an excess of circulating LCs 
produced by clonal plasma cells in the bone marrow; (ii) the hereditary transthyretin (TTR)-related 
amyloidosis (ATTRm) caused by deposition of mutant forms of the TTR protein, produced mainly 
by the kidney and corneas; and (iii) the wild-type TTR related amyloidosis (ATTRwt), also defined 
as “senile amyloidosis”, caused by deposition of non-mutant TTR protein in elderly patients [23]. 
Hence, we chose to target κ− and λ−LCs and TTR in our analysis. However, since κ−LCs,  λ-LCs 
and TTR are physiologically circulating proteins present in blood serum, identifying their presence 
in bioptic samples is not sufficient to make a conclusive diagnosis without also confirming the 
absence of blood serum in the sample being analyzed. While hemoglobin and albumin could have 
been employed as controls to signal blood serum inclusions, we instead chose to monitor peptide 
signatures of the constant regions of IgG Heavy Chains (HC)s, Types 1-4, since these full-
structured antibodies are normally present in blood serum and are also, generally, unrelated to 
amyloidosis [10]. Although MS analysis of IgGs can be troublesome due to various post-
translational modifications and poor reproducibility of proteolysis, this choice was influenced by 
their availability in our laboratory and our previous experience with their use. 
When amyloid and HC signals were detected in our analyzed samples, it provided suspicion of a 
blood serum inclusion, but for further verification we additionally evaluated the relative abundance 
of amyloid proteins in relation to tissue-specific proteins (i.e., actin (A) for CMT, and fatty acid 
binding protein 4 (FBP4) for SAT); the tenet being that in the presence of amyloid fibrils disrupting 
normal tissues, the relative abundance of these tissue-specific proteins would increase. By analyzing 
132 samples from known cases of amyloidosis with this approach, we were able to structure an 
algorithm to discriminate amyloid from non-amyloid affected tissues. 
2. Materials and methods 
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2.1. Chemicals, reagents and instruments 
Water, methanol (MeOH), 95 % ethanol (EtOH), acetonitrile (ACN), acetic acid (AcA), formic acid 
(FoA), xylene, tris(hydroxymethyl)-aminomethane hydrochloride (Tris-HCl), sodium dodecyl 
sulfate (SDS), dithyothreitol (DTT) were all LC-MS grade (VWR International Inc., Bridgeport, 
NJ, USA). Pure human polyclonal IgGs solution 12.5 mg/ml (81.7 nmol/ml), lyophilized TTR 
(reconstituted in-house to 1 mg/ml - 18 nmol/ml with water) and horse apomyoglobin (HA) 
(reconstituted in-house to 1.2 mg/ml - 69 nmol/ml with water) were from Sigma Aldrich (St. Louis, 
MO, USA).  
Amicon® centrifugal filter units were from Merck Millipore Ltd. (Tullagreen, Carrigtwohill, Co. 
Cork, IRL). Pierce™ In-Solution Tryptic Digestion Kits, Pierce™ C18 (100 µl) SPE Tips and 
Pierce™ Detergent Compatible Bradford Assay Kits  were obtained from Thermo Fisher Scientific 
(West Palm Beach, Florida, USA). 
The dry block heater used was from Thermo Fisher Scientific (West Palm Beach, FL, USA). 
Microcentrifuge 1.5 ml tubes and 5430 Microcentrifuges were from Eppendorf (Vienna,  
Austria). 
The LC column used was a reverse-phase Biobasic C18 column 5 µm, 50x2.1 mm (Thermo Fisher 
Scientific, West Palm Beach, FL, USA). The ultracentrifuge used was a 40R Megafuge (Thermo 
Fisher Scientific,West Palm Beach, FL, USA). 
LC was performed on a Shimadzu Nexera X2 UHPLC system (Shimadzu Corporation, Kyoto, 
Japan). 
Detection was performed using a Sciex 5500 Q-TRAP mass spectrometer equipped with a Turbo-V 
electrospray ionization (ESI) source (Sciex, Concord, Ontario, Canada) operated in positive 
electrospray (ESI+) MRM mode. Analyst 1.6.1 (Sciex, Concord, Ontario, Canada) was used for the 
system control, data acquisition, peak integration and quantification.  
 
2.2. Samples 
CMT biopsies were formalin fixed and paraffin embedded (FFPE) and kept in a histology 
repository at the Pathology Unit of the S.Orsola - Malpighi Hospital in Bologna. They were 
retrospectively analyzed using the developed LC-MS/MS approach.  
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Histological sections of CMT that were used for MS analysis were those that occurred in between 
two histological sections found to be positive for amyloid fibrils by a pathologist. Analysis of 
identical histological sections by the pathologist and mass spectrometrist was not feasible due to the 
preparation required by the pathologist for optical observation that included glue and a coverslip. 
SAT sample biopsies were brought to the laboratory in sterile vials after their sampling during “Out 
Patient” examinations. SAT samples were obtained by random puncture of the abdominal wall in 
the periumbilical region. Due to their size and nature, these samples could not be cut into serial 
histological sections and were analyzed as single entities by either the pathologist or the mass 
spectrometrist. 
Positive diagnosis was based on clinical evidence and histological observations (i.e., positive 
birefringence under polarized light after Congo red staining of fibrils). Amyloidosis subtypes were 
determined according to current diagnostic standards, including determination of the presence of 
concomitant plasma cell disorders, and immunohistochemistry for κ- or λ-LCs and TTR. 
 
2.3 CMT processing 
FFPE CMT, or glass microscope slides containing multiple microtome sections of CMT, were 
heated on a thermal block for 15 minutes at 60° C to melt any paraffin. Single microtome sections 
were then transferred into glass test tubes using a scalpel. Paraffin removal was completed by 
immersion in 1.5 ml of xylene in a glass test tube for 5 minutes with intermittent vortexing.  
Centrifugation at 0.78 G for 3 minutes followed, and the surnatant was discarded before fresh 
xylene was added. This washing was repeated 3 times. 
After xylene removal, tissue rehydration was performed by bathing the tissue in 1.5 ml of 95 % 
EtOH for 5 minutes with vortexing. Centrifugation at 0.78 G for 3 minutes followed and the 
surnatant was discarded prior to  fresh 95 % EtOH being added. This rehydration step was repeated 
twice. Tissue was further rehydrated by immersion into a 70-30% v/v EtOH-water solution, 
following the preceding procedure. Final rehydration was performed by immersion in water, again, 
following the procedure as described above. 
After water surnatant was removed, rehydrated CMT was digested at 90 °C overnight inside a 
screw-capped vial by adding 400 µl of a tissue digestion solution composed of 500 mM Tris-HCl 
plus 0.2% w/v SDS in water. 
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Following the overnight incubation, tubes were capped, clipped and placed at 105 °C for 2 hours on 
a dry-block heater. The resulting digested tissue broth was loaded onto 3 kDa cut-off ultra-filtration 
centrifugal filter units to remove detergents and other low-molecular-weight contaminants. 
Denatured protein solution (50 µL) was recovered from the filter and the protein concentration was 
determined using a Pierce™ Detergent Compatible Bradford Assay Kit. 
The protein solution was diluted with 50 mM Ammonium Bicarbonate buffer to yield a total protein 
concentration of 1 µg/µl. 
 
2.4 SAT processing 
SAT samples were weighed on an analytical balance. Fragments weighing more than 1 mg (dry 
weight) were cut into smaller pieces with a scalpel before being processed. No rehydration was 
needed for SAT samples, since they were immediately sent to the laboratory in a sterile vial without 
preservatives. Each tissue fragment (weighing less than 1 mg) was digested, following the same 
procedure used for the rehydrated CMT, by immersing it in 400 µl of the tissue digestion solution 
and incubating at 90° C overnight in a screw-capped vial. Following the overnight incubation, the 
resultant tissue broth was processed as noted in section 2.3 for CMT to yield a total protein 
concentration solution of 1 µg/µl. 
 
2.5 Tryptic Digestion and Peptide Extraction 
A 10 µl aliquot of the 1 µg/µl total protein solution obtained following 2.3 or 2.4 , as described 
above, was spiked with a 2 µl aliquot of HA solution (3.45 nmol/ml in water) as an internal 
standard and processed according to the manufacturer’s instructions for the Tryptic Digestion Kit. 
In brief, reduction was conducted in a buffer composed by 50 mM ammonium bicarbonate and 100 
mM DTT at 95°C for 5 minutes. Alkylation was conducted by adding 3 µl of 100 mM 
iodoacetamide solution at room temperature for 20 minutes in the dark. Finally, trypsin digestion 
was performed with a serine protease (from porcine pancreatic extracts) in buffered solution (100 
ng/µl) added in a trypsin:protein 1:20 w/w ratio at 37°C for at least 2 hours, or overnight for higher 
reaction yields. 
Peptides were extracted by C18 SPE tips according to the manufacturer’s instructions. The final 
elution volume was 20 µL of a solution composed by 0.1% v/v FOA in ACN. 
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2.6 Liquid Chromatography 
The purified peptide solution was diluted 1:4 v/v with mobile phase A (0.1% v/v FOA in water) 
before injection. The injection volume was 20 µl. A simple binary concentration gradient on a 
Biobasic C18 column was suitable for peptide detection. Phase B (0.1% v/v FOA in ACN) was held 
at 0% for 0.5 minutes, and then increased to 95% over 3 minutes, held at 95% for 0.5 minutes, 
decreased to 0% over 0.01 minutes and then held at 0% for 0.49 minutes. Total run time was 4.0 
minutes. The flow rate was held constant at 0.5 ml/min. 
 
2.7 Tandem mass spectrometry 
ESI ion source parameters strongly depend on chromatographic flow and were held constant during 
the run. They were: curtain gas =20 psi, ion spray voltage= 5500 V, temperature = 550 °C, GS1= 30 
psi, GS2= 50 psi. MS/MS transitions for all peptides of interest were retrieved from the SRMAtlas 
database (www.srmatlas.org).[24], except  for the horse HA protein, MRM transitions were 
retrieved on another database at www.ionsource.com. Transition-specific parameters for the API 
5500 were optimized experimentally by syringe infusion of purified peptides obtained by tryptic 
digestion of pure proteins. The declustering potential and collision energies, in particular, were 
optimized over successive LC-MS/MS runs in order to take into account possible effects of the 
change in mobile phase composition during the chromatographic gradient that could not be 
accurately modeled by syringe infusion. 
 
3. Results 
A fundamental initial step in this work was optimizing multiple reaction monitoring (MRM) 
transition-specific parameters for proteotypic peptides. For each targeted protein, at least three 
different proteotypic peptides needed be monitored to meet requirements for use in clinical 
applications[20]. For each peptide, various transitions are available on internet databases. We found 
usable transitions to be in the 5-1250 m/z range, due to the limits of the mass axis for the API 5500 
instrument in MRM mode. After experimental verification with default transition-specific 
parameters typically employed with our system (i.e., DP=110, EP=10, CE=35, CXP=15), two 
transitions were selected for each peptide,  among those available: a quantifier (characterized by the 
most intense response in our mass spectrometer), and a qualifier (with a less intense response). 
Transition-specific parameters were optimized in two phases: first, by syringe infusion of tryptic 
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digests of pure protein mixtures (at a concentration of 1 nM each); and second, by injection of the 
same tryptic digests in successive chromatographic runs while varying parameters of the ESI ion 
source (e.g., GS1, GS2, Ion source temperature, Ion Voltage), and then of the mass spectrometer 
(e.g., DP and CE, in particular)in successive chromatographic runs. The results of the tuning on our 
API 5500 are reported in Table 1. 
Coincident retention times for the quantifier and the qualifier transitions and their ion extraction 
chromatogram (XIC) peak area ratios were used as identifying features for proteotypic peptides 
monitored in MRM mode. Mean values of these parameters, obtained by the analysis of 10 
independent pure protein mixtures containing 1 nmol/ml of each protein, are reported in Table 2. 
Typical XICs obtained in the analysis of pure commercial human TTR (1 nmole/ml in water) are 
reported in Figure 1A. XICs obtained in the analysis of pure commercial human IgG (1 nmole/ml in 
water) are reported in Figure1 B, C and D, and show simultaneous detection of k, λ-LC and HCs 
peptide signatures, as expected. 
Typical XIC traces obtained in the analysis of non-amyloid CMT and SAT samples are reported in 
Figures 2 and 3, respectively, as examples. Essentially negative signals (very low absolute y-axis 
scale counts) for TTR, k-LCs, λ-LC and HCs, as those in Figure 2A, B, C, and D, respectively, 
were associated with a negligible (at least to the aims of the present study) presence of these 
proteins in the sample. Peaks, as those in Figure 2E, confirming the presence of A in CMT samples, 
were taken as an indication of the overall efficiency of the analytical steps. Similarly, signals for 
TTR, k-LCs, λ-LC and HCs, as those in Figure 3A, B, C, and D, respectively, were considered 
negative, whereas relatively intense peaks in Figure 3E, with expected relative area ratio of their 
transitions, were associated with the presence of the FBP4 peptides in SATs. Peptides belonging to 
the non-human protein HA, spiked in each digested tissue, as indicated in section 2.5, were detected 
with an almost constant intensity in every sample, as in Figure 2F or 3F. Even higher signals for 
TTR, k and λ-LC could be detected in about 20% of non-amyloid CMT and SAT samples (data not 
shown), most probably due to the presence of blood serum; a hypothesis supported by the detection 
of HC in these samples. 
The matrix effect on peptide MS/MS signals was evaluated by comparing qualifier transition XIC 
mean peak areas obtained in the analysis of: (i) 1 nmol each mixture of pure proteins after tryptic 
digestion; (ii) 1 nmol each mixture of pure proteins spiked into denaturated protein mixture 
obtained (method 2.3) from CMT before performing method 2.5; (iii) 1 nmol each mixture of pure 
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proteins spiked into denaturated proteins mixture (see method 2.4) from SAT before performing 
method 2.5. Analyses were performed in triplicate and mean results are reported in Table 3. 
The limit of detection (LOD) for each peptide was evaluated by successive dilutions of pure peptide 
mixtures, spiked before performing tryptic digestion and peptide extraction of non-amyloid CMTs 
or SATs, until the recorded signal-to-noise ratio for the qualifier transition of each peptide was > 3. 
Results of these experiments are reported in Table 4. Sub-picomole sensitivity, in matrix, was 
achieved for all targeted peptides. 
Typical XICs obtained in the analysis of an amyloid (i.e., ATTR) CMT sample are reported in 
Figure 4. Marked signals for TTR in Figure 4A could be linked to its pathological presence in the 
bioptic specimen. Low level k- and λ-LCs and HCs signals, as in Figures 4B, C and D, respectively, 
may indicate blood serum inclusions in this CMT. The presence of A and HA signals, similar to 
those in Figures 2E and F, were a confirmation of the efficiency of the analytical process. 
Typical XICs obtained in the analysis of one SAT sample in a case of AL amyloidosis are shown in 
Figure 5. κ-LC signal peaks in Figure 5C were ascribed to the presence of pathological inclusion of 
λ-LCs in this bioptic sample. Very low signals for TTR, k-LCs and HCs, as in Figure 5A, B and D, 
respectively, may indicate blood serum inclusions in this SAT. FBP4 and HA peaks, as those in 
Figure 3E and F, respectively, were used to confirm the efficiency of the analytical process. 
To more effectively evaluate whether detection of amyloid proteins is a function of the presence of 
amyloid fibrils and/or blood serum inclusions in tissues, we calculated the relative abundance of  
amyloid versus tissue-specific proteins (i.e., A for CMT or FBP4 for SAT) based on their 
normalized relative area ratios in a number of pathological vs. non-pathological samples. However, 
since our method is qualitative, it was necessary to evaluate relative protein abundances based on 
normalized peak areas in our XICs. And, since the mass spectrometer responds with different 
sensitivity to different peptides, peak areas were normalized among peptides belonging to the same 
protein using response ratios measured in standard mixtures (see Table 2, column 5) in order to 
express a unique ratio value. Ratio values were further normalized to the relative internal standard 
(i.e., HA) peak area among samples to correct for variations in the efficiency of analytical steps. 
Average ratios of amyloid to tissue-specific proteins, as calculated, are shown for CMT and SAT, in 
Tables 5 and 6, respectively. 
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4. Discussion 
Here, we present a targeted proteomics approach for typing cases of amyloidosis that are the most 
frequently encountered in our clinical practice. To achieve this we first identified proteotypic 
peptide signatures for targeted proteins. The historical approach to determine signature MRM 
transitions has been to identify them with an HR-MS/MS instrument and then tentatively 
extrapolate to lower resolution triple quadrupole instruments. Currently, however, thanks to open 
source bioinformatics tools that are readily available on the internet, transitions for a large number 
of proteotypic peptides are easily accessible. In the present study, we used the SRMAtlas database 
(www.srmatlas.org), from which we were able to retrieve MRM transitions for all of our targeted 
human proteins, as determined using the same type of mass spectrometer as we employ in this 
study; whereas, for the horse HA protein, MRM transitions were retrieved on a different website 
(www.ionsource.com). This information contributed greatly towards accelerating our progress 
during the early stages of this project. Three signature peptides, a number considered to be minimal 
confidence measure for clinical proteomic applications [20], were used to confirm identification of 
each of the targeted proteins. However, when employing only three peptides, most of the primary 
sequence of the targeted proteins is not covered, hence, intrinsic limitations of the method for the 
purpose of qualitative protein identification must be considered. For instance, the possibility of 
detecting truncated protein forms, which could constitute certain amyloid fibrils [10], is clearly 
impaired. Likewise, the possibility of identifying point mutations in targeted peptides can only be 
indirect, with homozygous and heterozygote mutations leading to either complete ablation or a 50% 
reduction in the corresponding peptide's signal, respectively. In our experiments, we were able to 
observe the absence of the GSPAINVAVHVFR peptide signals in two cases of TTR-m 
amyloidosis, in which a methionine-30 transthyretin variant was known from previous genetic 
analysis (data not shown). Additional coverage of the primary sequence would greatly improve 
specificity of a targeted approach, such as that described here, but will require the availability of 
additional peptide MRM transitions (for mutated peptides as well). 
Proteotypic peptide identification parameters in targeted mode included: (i) the presence of peaks 
with a signal-to-noise >3 in the XICs of both the quantifier and the qualifier transition, (ii) 
coincidence of their retention time, and (iii) a characteristic peak area ratio. We adopted a tolerance 
of 2% for retention time and 10% for the quantifier over qualifier area. These identification criteria 
were used as we proceeded to optimize the chromatographic conditions. 
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Chromatographic conditions were a compromise between analytical speed and sensitivity, since fast 
chromatography is usually the option of choice in clinical chemistry applications. Ion suppression 
due to peptide and/or matrix component co-elution did not compromise sensitivity or specificity in 
our method. Various run times and gradient elution rates (in the 0.1-1 B%/sec range) were tested. 
Longer runs did not considerably improve sensitivity to targeted peptides. This was possibly due to 
the strong ionizing conditions employed in the ESI source (i.e., 5500 V and 550° C) that enabled 
maximum ion yields even in conditions of potential co-elution. The effect of different acids in the 
mobile phases was tested in order to further amplify ion yields. FOA at 0.1% v/v in both phases 
provided improved signal intensity compared to TCA 0.1% or a 50-50% v/v mixture of the two. 
Additionally, higher acid concentrations resulted in lower signals, most likely due to an increase in 
multi-charged ions of the same peptides. 
Various total LC flows were tested in the 0.1-1 ml range. This parameter substantially altered MRM 
signal intensity and peak width. A total flow of 0.5 ml/min provided an optimal peak area/width 
ratio and signal intensities for all MRM signals for the LC column employed. Other 
chromatographic columns were tested and resulted in differing elution series and peak shapes, but a 
sensitivity gain  was not observed. ACN as the B phase was selected because it provided lower back 
pressure in the LC system when compared to MeOH, without substantial variations in signal 
intensity or elution order with the same gradient. Optimization of these experimental conditions 
enabled us to reach acceptable sensitivities for all targeted proteins for both CMT and SAT (Table 
3). 
To investigate potential ion suppression in the ESI source due to a matrix effect, we also performed 
a post-column infusion experiment in which a tryptic digest of pure proteins (1 nmole each) was 
infused post-column by means of the API 5500 integrated syringe pump at a constant flow of 10 
µl/min, while a tryptic digest of CMT and SAT was injected on-column. Signal intensity in the 
XICs was within ± 20% during the 5 minute run, essentially confirming the level of signal 
suppression/amplification seen in the experiment for all peptides (Table 3). Based on these results, 
we concluded that ion suppression in the ESI source was limited and did not dramatically impair 
detection sensitivity. 
In order to monitor the efficiency of the pre-analytical steps for the proposed method, a non-human 
protein (HA) was used as an internal standard. This choice was clearly a compromise since 
isotopically labeled pure proteins, or at least labeled peptides, would have been a better option. 
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However, our experimental data indicated that this was an acceptable substitute. Furthermore, even 
if we could follow the ideal path of using isotopically labeled proteins it would still not achieve 
precise quantitative tissue analysis. In actuality, to monitor overall tissue processing accuractely 
would require isotopically labeled amyloid fibrils embedded in tissues, which is not an available 
option. However, by monitoring the presence of common tissue specific proteins (i.e., A for CMT 
and FBP4 for SAT) we were able to gain insight into tissue digestion efficiency. Indeed, tissue 
processing conditions were optimized by monitoring the A or FBP4 signals on different fragments 
of the same non-amyloid bioptic specimens by varying sensible parameters such as rehydrating 
conditions, digestion buffer composition, digestion temperature and duration. Parameters presented 
in section 2.3 are those that resulted in optimal yields in term of A and FBP4 signals. 
In practice, it was necessary to evaluate method sensitivity as the ability to efficiently process our 
smallest bioptic samples, which were single histological sections 2 µm thick (and about 2-3 mm in 
diameter), fixed and stained on histological glass slides. Acceptable tissue protein concentration 
(above 10 ug/ml) was always obtained, even after processing our smallest samples. 
Tryptic digestion and peptide extraction conditions reported in section 2.5 were those suggested in 
the producers' manual. We did not attempt variations of the suggested parameters. We only tested 
the effect of different dilution procedures on extracted peptides. The 1:4 v/v dilution with mobile 
phase improved peak shape, intensity, and retention time stability compared with undiluted, smaller 
volume injections. 
To confirm the specificity of our proposed method in the evaluation of amyloidosis, without the aid 
of LMD to pick-out amyloid fibrils from histology sections, it was necessary to acknowledge the 
fact that k-, λ-LCs and TTR are also circulating in the blood of patients without amyloidosis and 
could, thus, be present in non-amyloid tissues as a result of blood serum inclusions. To address this 
possible interference, we also measured HC peptide signatures that we found to be reliable monitors 
of the presence of serum contamination in tissues. 
However, the determination of serum contamination, in addition to the presence of k-LCs, λ-LCs or 
TTR does not, in itself, negate a diagnosis of amyloidosis, it only creates doubt as to the source of 
the proposed amyloid markers. Are they from a pathological process (i.e., amyloidosis) or are they 
from the serum of an otherwise healthy individual? Hence, with a finding of HC, in combination 
with the amyloid markers, it is necessary to take further measures to confirm the presence, or 
absence, of amyloidosis. Our solution was to measure the abundance of the amyloid marker proteins 
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relative to tissue-specific proteins. As mentioned in the Results section, it is expected that increased 
presence of amyloid fibrils within tissues would disrupt the surrounding tissue and resulti in an 
decrease in the levels of normal tissue proteins. Since our method is qualitative, we used a 
normalized peak area ratio in this evaluation. By analyzing 132 samples from AL, ATTR and 
mixed-type amyloidosis patients we observed that area ratio values (for each of the three protein 
ratios showed in Table 5) in amyloid tissues were significantly higher than corresponding values in 
non-amyloid ones (p < 0.05, unpaired T-test). This was true both in CMTs and in SATs (Tables 5 
and 6, respectively). 
Although the average ratios were significantly different between amyloid and non-amyloid tissues, 
there were few instances where we found low ratio values in amyloid cases that were confirmed by 
other means. These discrepancies were ascribed to the fact that since amyloidosis deposits are not 
evenly distributed in tissues, the bioptic sampling can sometimes probe an unaffected zone by 
chance. As a confirmation of our hypothesis, we analyzed independent SAT samples from the same 
amyloidosis patients with the mass spectrometry method proposed here and observed positive 
results in most cases, but also a few negatives among them.  
 
5. Conclusions 
Here, we present a targeted proteomics approach for specifically and sensitively detecting targeted 
amyloid proteins in bioptic specimens (both CMT and SAT) taken from AL, ATTR or mixed type 
amyloidosis affected patients. We believe that this approach could be a useful analytical tool for 
smaller to mid-size clinical laboratories that are not equipped with LMD and high resolution mass 
spectrometry for amyloid typing, as are larger proteomics reference centers. 
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Captions to Figures and Tables 
 
Table 1. MRM transition specific parameters. 
For each protein, in column 1, proteotypic peptide transition names, in column 2, have been given 
by peptide primary sequence (position in brackets) followed by a suffix reflecting signal intensity 
and intended use (quant for the more intense, qual for the less intense). Parent ion apparent mass 
(selected by the first quadrupole, Q1) and daughter ion apparent mass (selected by the third 
quadrupole, Q3) are reported in columns 3 and 4, respectively. Optimized transition specific 
parameters were common for all transitions on the API 5500 system were: dwell time (DT) = 10 ms, 
  
19 
 
declustering potential (DP) = 110 V, entrance potential EP = 10 V, collision exit potential CXP = 
15 V. The Collision energy (CE), determining considerable signal variation, is reported in column 
5. 
 
Table 2. Proteotypic peptide identifying parameters. 
For each protein (column 1) peptides (column 2) with parent ion and daughter ion apparent masses 
(columns 3 and 4, respectively) quant and qual transition coincident retention times are reported in 
column 5. Quant over qual transition relative intensity (XIC area ratios) are reported in column 6. 
Overall relative intensities of each transition belonging to the same protein are reported in column 
7. 
 
Table 3. Estimation of the matrix effect on XICs. 
Mean peak area (N=3) of qual transitions obtained in the analysis of: a) 1 nmol each mixture of 
pure proteins in carbonate buffer after tryptic digestion; b) 1 nmol each mixture of pure proteins 
spiked into denaturated protein mixture obtained (method 2.3) from CMT before performing 
method 2.5; c) 1 nmol each mixture of pure proteins spiked into denaturated proteins mixture (see 
method 2.4) from SAT before performing method 2.5, d) percent response (b area / a area) in the 
CMT matrix, e) percent response (c area / a area) in the SAT matrix. 
 
Table 4. Analytical sensitivity. 
For each protein (column 1) and proteotypic peptides (column 2) analytical limits of detection 
(LODs) observed in the CMT and in the SAT matrices are reported in column 3 and 4, respectively. 
They were obtained by analysis of successive dilution of pure protein solutions spiked into 
denaturated proteins mixture from CMT or SAT (according to method 2.3 or 2.4) before tryptic 
digestion (method 2.5) until recorded signal to noise (S/N) ≥ 3. 
 
Table 5 Amyloid over CMT-specific protein normalized peak area ratios. 
Relative abundance of indicated amyloid proteins over A (in column 1) have been calculated by 
means of peak area ratios (normalized by peptide relative response and internal standard (HA) 
sample relative intensity) obtained in the analysis of non-amyloid (column 2) and amyloid CMTs 
(column 3). The number of examined cases, reported in brackets, was a function of sample 
availability. 
 
Table 6 Amyloid over SAT-specific protein normalized peak area ratios. 
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Relative abundance of indicated amyloid proteins over FABP4 (in column 1) have been calculated 
by means of peak area ratios (normalized by peptide relative response and internal standard (HA) 
sample relative intensity) obtained in the analysis of non-amyloid (column 2) and amyloid SATs 
(column 3). The number of examined cases (in brackets) was a function of sample availability. 
 
Figure 1. Typical XICs recorded in MRM mode of pure proteins. 
XICs obtained in the analysis of a solution of pure commercial human TTR (1 nmole/ml in carbonate 
buffer) showing intense signals for TTR proteotypic peptides (in A) and of a solution of pure 
commercial human polyclonal IgGs (1 nmole/ml in carbonate buffer) showing peptide signals for k, 
λ-LC and HCs (in B, C and D, respectively). 
 
Figure 2. Typical XICs of non-amyloid CMT. 
XICs obtained in the analysis of a typical non-amyloid CMT. TTR, k-LCs, λ-LC and HCs signals in 
A, B, C, and D, respectively, were very low (confront cfr. absolute y-axis scale count values). Peaks 
in 2E clearly attested the presence of the A in the sample. The exogenous non-human protein (HA) 
spiked in the digested tissue was accordingly detected in 2F. 
 
Figure 3. Typical XICs of non-amyloid SAT. 
XICs obtained in the analysis of a non-amyloid SAT. TTR, k-LCs, λ-LC and HCs signal intensities 
in 3A, B, C, and D, respectively, were negligible (very low absolute y-axis scale counts). Peaks in 
3E clearly confirmed the presence of the FBP4 in the sample. The exogenous non-human protein 
(HA) spiked in the digested tissue was accordingly detected in 3F. 
 
Figure 4. Typical XICs of amyloid CMT. 
XICs obtained in the analysis of an amyloid (ATTR amyloidosis) CMT sample. Marked signals for 
TTR were detected, as shown in 4A. Low level k-, λ-LCs and HCs signals in 4B, C and D, 
respectively, were probably due to blood serum inclusions in this CMT sample. Peaks in 4E 
attesting the presence of the A in the sample confirmed the efficiency of the overall analytical 
process. The exogenous non human protein (HA) spiked in the digested tissue was accordingly 
detected in 4F. 
 
Figure 5. Typical XICs of amyloid SAT. 
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XICs obtained in the analysis of an amyloid (AL amyloidosis) SAT sample. λ-LC peaks in 5C 
could be attributed to the presence of this type of amyloid protein in the sample. Low signals for 
TTR, k-LCs and HCs in 5A, B and D, respectively, (confront cfr. very low absolute y-axis scale 
counts) were probably due to blood serum inclusions in this SAT sample. Peaks in 5E attesting the 
presence of the FBP4 in the sample, confirmed the efficiency of the overall analytical process. The 
exogenous non human protein (HA) spiked in the digested tissue was accordingly detected in 5F. 
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PROTEIN TRANSITION ID Q1 (m/z) Q3 (m/z) 
CE 
(volts) 
TTR(P02766) 
GSPAINVAVHVFR (22-34) quant  697.8 606.3 40 
GSPAINVAVHVFR (22-34) qual  697.8 921.4 32 
AADDTWEPFASGK (36-48) quant 683.9 941.5 40 
AADDTWEPFASGK (36-48) qual 683.9 827.5 40 
ALGISPFHEHAEVVFTANDSGPR (81-103) quant 613.6 416.0 35 
ALGISPFHEHAEVVFTANDSGPR (81-103) qual 613.6 645.3 35 
k-LC(P01834) 
TVAAPSVFIFPPSDEQLK (1-18) quant  973.5 913.5 50 
TVAAPSVFIFPPSDEQLK (1-18) qual  973.5 272.2 45 
SGTASVVCLLNNFYPR (19-34) quant  899.4 272.2 35 
SGTASVVCLLNNFYPR (19-34) qual  899.4 810.4 35 
DSTYSLSSTLTLSK (62-78) quant 751.9 836.5 35 
DSTYSLSSTLTLSK (62-78) qual 751.9 448.3 35 
λ-LC(P0CG04) 
ATLVCLISDFYPGAVTVAWK (24-43) quant  872.4 687.3 40 
ATLVCLISDFYPGAVTVAWK (24-43) qual  872.4 788.4 35 
YAASSYLSLTPEQWK (66-80) quant  737.7 464.7 25 
YAASSYLSLTPEQWK (66-80) qual  737.7 928.5 30 
AAPSVTLFPPSSEELQANK (107-125) quant 993.5 787.4 35 
AAPSVTLFPPSSEELQANK (107-125) qual 993.5 640.4 35 
HCs(P01857) 
GPSVFPLAPSSK (5-16) 593.8 699.4 25 
GPSVFPLAPSSK (5-16) 593.8 846.5 25 
DTLMISR (132-138) quant  418.3 619.4 25 
DTLMISR (132-138) qual 418.3 506.3 20 
TTPPVLDSDGSFFLYSK (276-293) 625.3 657.4 25 
TTPPVLDSDGSFFLYSK (276-293) 625.3 397.2 25 
A(P62736) 
AGFAGDDAPR (21-30) quant  488.7 343.2 35 
AGFAGDDAPR (21-30) qual 488.7 458.2 30 
AVFPSIVGR (40-49) quant 473.3 628.4 30 
AVFPSIVGR (40-49) qual 473.3 531.3 30 
ETTALAPSTMK (281-291) quant 581.3 634.3 30 
ETTALAPSTMK (281-291) qual 581.3 379.2 35 
FABP4(P15090) 
LVSSENFDDYMK (11- 32) quant 724.3 1235.5 30 
LVSSENFDDYMK (11- 32) qual 724.3 213.2 35 
EVGVGFATR (32-41) quant 468.3 551.3 30 
EVGVGFATR (32-41) qual 468.3 707.4 30 
NTEISFILGQEFDEVTADDR (59-79) quant 767.0 577.3 30 
NTEISFILGQEFDEVTADDR (59-79) qual 767.0 805.4 30 
HA (P68082) 
GLSDGEWQQVLNVWGK (2-17) quant 908.5 390.4 40 
GLSDGEWQQVLNVWGK (2-17) qual 908.5 716.6 40 
VEADIAGHGQEVLIR (21 33) quant 804.0 1009.0 40 
VEADIAGHGQEVLIR (21-33) qual 804.0 815.0 40 
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 HGTVVLTALGGILK (65-78) quant 690.0 886.0 40 
 HGTVVLTALGGILK (65-78) qual 690.0 985.0 40 
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protein transition id Q1 (m/z) Q3 (m/z) retention time (min) peak area ratio   relative response 
TTR(P02766) 
GSPAINVAVHVFR (22-34) quant  697.8 606.3 
1.90 1.3 
12.0 
GSPAINVAVHVFR (22-34) qual  697.8 921.4 7.0 
AADDTWEPFASGK (36-48) quant 683.9 941.5 
1.88 6.9 
6.9 
AADDTWEPFASGK (36-48) qual 683.9 827.5 1.0 
ALGISPFHEHAEVVFTANDSGPR (81-103) quant 613.6 416.0 
1.86 3.0 
6.0 
ALGISPFHEHAEVVFTANDSGPR (81-103) qual 613.6 645.3 2.1 
k-LC(P01834 
TVAAPSVFIFPPSDEQLK (1-18) quant  973.5 913.5 
2.05 1.2 
8.5 
TVAAPSVFIFPPSDEQLK (1-18) qual  973.5 272.2 7.0 
SGTASVVCLLNNFYPR (19-34) quant  899.4 272.2 
2.15 1.1 
1.8 
SGTASVVCLLNNFYPR (19-34) qual  899.4 810.4 1.5 
DSTYSLSSTLTLSK (62-78) quant 751.9 836.5 
1.88 2.0 
2.0 
DSTYSLSSTLTLSK (62-78) qual 751.9 448.3 1.0 
λ-LC(P0CG04) 
ATLVCLISDFYPGAVTVAWK (24-43) quant  872.4 687.3 
1.97 1.1 
8.0 
ATLVCLISDFYPGAVTVAWK (24-43) qual  872.4 788.4 7.5 
YAASSYLSLTPEQWK (66-80) quant  737.7 464.7 
2.27 1.5 
1.5 
YAASSYLSLTPEQWK (66-80) qual  737.7 928.5 1.0 
AAPSVTLFPPSSEELQANK (107-125) quant 993.5 787.4 
1.90 4.0 
8.0 
AAPSVTLFPPSSEELQANK (107-125) qual 993.5 640.4 2.0 
HCs(P01857) 
GPSVFPLAPSSK (5-17) quant  593.8 699.4 
1.90 1.1 
4.5 
GPSVFPLAPSSK (5-17) qual 593.8 846.5 4.0 
DTLMISR (132-138) quant  418.3 619.4 
1.78 3 
3.0 
DTLMISR (132-138) qual 418.3 506.3 1.0 
TTPPVLDSDGSFFLYSK (276-293) quant  625.3 657.4 2.04 1.1 2.9 
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TTPPVLDSDGSFFLYSK (276-293) qual 625.3 397.2 2.8 
A(P62736) 
AGFAGDDAPR (21-30) quant  488.7 343.2 
1.65 1.5 
6.5 
AGFAGDDAPR (21-30) qual 488.7 458.2 4.0 
AVFPSIVGR (40-49) quant 473.3 628.4 
1.92 1.8 
7.1 
AVFPSIVGR (40-49) qual 473.3 531.3 4.5 
ETTALAPSTMK (281-291) quant 581.3 634.3 
1.80 1.5 
1.5 
ETTALAPSTMK (281-291) qual 581.3 379.2 1.0 
FABP4(P15090) 
LVSSENFDDYMK (11- 32) quant 724.3 1235.5 
1.85 1.2 
2.0 
LVSSENFDDYMK (11- 32) qual 724.3 213.2 1.5 
EVGVGFATR (32-41) quant 468.3 551.3 
1.75 2 
12.0 
EVGVGFATR (32-41) qual 468.3 707.4 8.0 
NTEISFILGQEFDEVTADDR (59-79) quant 767.0 577.3 
2.15 1.2 
1.2 
NTEISFILGQEFDEVTADDR (59-79) qual 767.0 805.4 1.0 
HA (P68082) 
GLSDGEWQQVLNVWGK (2-17) quant 908.5 390.4 
2.12 2.5 
7.0 
GLSDGEWQQVLNVWGK (2-17) qual 908.5 716.6 2.8 
VEADIAGHGQEVLIR (21 33) quant 804.0 1009.0 
1.80 1.1 
1.1 
VEADIAGHGQEVLIR (21-33) qual 804.0 815.0 1.0 
 HGTVVLTALGGILK (65-78) quant 690.0 886.0 
2.05 1.1 
3.5 
 HGTVVLTALGGILK (65-78) qual 690.0 985.0 3.0 
 
 
 
transition id 
a (peak 
area) b (peak area) c (%) c (peak area) d (%) 
GSPAINVAVHVFR (22-34) qual  85350 110955 130 81709 96 
AADDTWEPFASGK (36-48) qual 69152 56511 82 79411 115 
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ALGISPFHEHAEVVFTANDSGPR (81-103) qual 40255 35244 88 37988 95 
TVAAPSVFIFPPSDEQLK (1-18) qual  39700 39224 99 37377 94 
SGTASVVCLLNNFYPR (19-34) qual  21520 46525 216 46912 218 
DSTYSLSSTLTLSK (62-78) qual 14965 9763 65 13222 88 
ATLVCLISDFYPGAVTVAWK (24-43) qual  30450 20423 68 17051 58 
YAASSYLSLTPEQWK (66-80) qual  9980 4033 40 4230 42 
AAPSVTLFPPSSEELQANK (107-125) qual 17215 7828 45 10119 59 
GPSVFPLAPSSK (5-17) qual 101244 75225 75 69256 69 
DTLMISR (132-138) qual 20956 14057 69 12977 65 
TTPPVLDSDGSFFLYSK (276-293) qual 59967 43123 72 42899 73 
GLSDGEWQQVLNVWGK (2-17) qual 9998 9494 95 9145 91 
VEADIAGHGQEVLIR (21-33) qual 4858 5201 105 5004 103 
 HGTVVLTALGGILK (65-78) qual 12021 13051 110 12784 102 
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protein proteotypic peptide LOD (pmoli) LOD (pmoli) 
TTR 
GSPAINVAVHVFR (22-34) 0.10 0.10 
AADDTWEPFASGK (36-48) 0.20 0.20 
ALGISPFHEHAEVVFTANDSGPR (81-103) 1.00 0.20 
k-LC 
TVAAPSVFIFPPSDEQLK (1-18) 0.05 0.10 
SGTASVVCLLNNFYPR (19-34) 0.10 0.10 
DSTYSLSSTLTLSK (62-78) 0.10 0.10 
λ-LC 
ATLVCLISDFYPGAVTVAWK (24-43) 0.05 0.10 
YAASSYLSLTPEQWK (66-80) 0.20 0.10 
AAPSVTLFPPSSEELQANK (107-125) 0.20 0.50 
 
 
 
Protein ratio / tissue type 
non-amyloid 
CMT amyloid CMT 
avg ± std. (N) avg ± std. (N) 
TTR/A 0.02±0.002 (50) 5.07±0.45 (51) 
k-LC/A 0.26±0.02 (50) 8.57±0.55 (22) 
λ-LC/A 0.05±0.003 (50) 1.10±0.51 (18) 
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Protein ratio / tissue type 
non-amyloid SAT amyloid SAT 
avg ± std. (N) avg ± std. (N) 
TTR/FABP4 0.32±0.24 (20) 1.27±0.51 (12) 
k-LC/FABP4 0.76±0.26 (20) 2.47±0.66 (15) 
λ-LC/FABP4 0.34±0.25 (20) 4.51±0,45 (14) 
 
